ECG vs FSS

ECG exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and impressive growth metrics, including 60.2% YoY earnings growth. However, the stock is significantly overvalued, trading at $136.06—well above its Graham Number ($33.13) and Intrinsic Value ($116.53). While profitability is strong with an ROE of 38.34%, the technical trend is heavily bearish (10/100), suggesting the recent 232% one-year rally may have peaked. The valuation premium is high, and the current price exceeds the analyst target of $131.50.

FSS exhibits a stable financial profile with a Piotroski F-Score of 4/9 and a current price ($116.01) trading almost exactly at its growth-based intrinsic value ($118.29). The company demonstrates exceptional operational momentum with 26.5% YoY revenue growth and a remarkable 25-quarter track record of earnings beats. While the Graham Number suggests a significant defensive discount, the market is pricing in high growth expectations supported by a strong ROE of 19.2% and a very healthy balance sheet. Despite bearish technicals and recent insider selling, the fundamental growth trajectory and analyst consensus remain strongly positive.